Editas Medicine, Inc.
Clinical-stage gene-editing company developing EDIT-401, a liver-targeted in vivo CRISPR/Cas9 candidate designed to increase hepatic LDLR expression for heterozygous familial hypercholesterolemia.
Cardiovascular / Genetic Medicine · In vivo CRISPR/Cas9 gene editing · Late preclinical / planned Phase 1/2